)
Sanofi Pasteur, the vaccine division of Sanofi, announced today its affiliate Shantha Biotechnics had delivered the first 400,000 doses of pediatric Pentavalent vaccine Shan5 to support immunisation of children in cities of Gwalior and Jabalpur in Madhya Pradesh.
Shantha was awarded by global health organisations to supply 37 million doses of Shan5 in 2015 and 2016 in a ten-dose vial presentation, the company said. The vaccine will be used in the routine immunisation programmes of a number of countries enabling up to 10 million children to receive protection from five pediatric diseases, it said.
"This supply illustrates how Shantha and Sanofi Pasteur meet public health needs", said Olivier Charmeil, president of CEO of Sanofi Pasteur. "We are proud to contribute to making high-quality vaccines accessible to more children in developing countries."
"We are pleased to have obtained this first tender award since Shan5 was registered and WHO-prequalified in April 2014,"said Harish Iyer, CEO of Shantha. As one of the strategic manufacturing platforms for Sanofi Pasteur, Shantha was delivering on its commitment to serve health needs and provide access in under-served vaccine markets, according to him.
